# Phase 1/2 Lyme Vaccine Study

> **NCT01504347** · PHASE1,PHASE2 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 1630 (actual)

## Conditions studied

- Prophylaxis of Lyme Borreliosis

## Interventions

- **BIOLOGICAL:** Multivalent recombinant OspA Lyme Borreliosis Vaccine
- **BIOLOGICAL:** Multivalent recombinant OspA Lyme Borreliosis Vaccine
- **BIOLOGICAL:** Multivalent recombinant OspA Lyme Borreliosis Vaccine

## Key facts

- **NCT ID:** NCT01504347
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-01
- **Primary completion:** 2011-09-13
- **Final completion:** 2014-02-28
- **Target enrollment:** 1630 (ACTUAL)
- **Last updated:** 2021-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01504347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01504347, "Phase 1/2 Lyme Vaccine Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01504347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*